Rasuvo and Weakness - a phase IV clinical study of FDA data

Summary:

Weakness is reported as a side effect among people who take Rasuvo (methotrexate), especially for people who are female, 60+ old, have been taking the drug for 1 - 6 months also take Proair Hfa, and have Rheumatoid arthritis.

The phase IV clinical study analyzes which people have Weakness when taking Rasuvo. It is created by eHealthMe based on reports of 3,515 people who have side effects when taking Rasuvo from the FDA, and is updated regularly.

What is Rasuvo?

Rasuvo has active ingredients of methotrexate. It is often used in psoriatic arthritis. eHealthMe is studying from 3,702 Rasuvo users. Check the latest studies of Rasuvo.

What is Weakness?

Weakness is found to be associated with 3,642 drugs and 6,611 conditions by eHealthMe. Check the latest studies of Weakness.

On Jul, 10, 2026

3,515 people reported to have side effects when taking Rasuvo.
Among them, 42 people (1.19%) have Weakness.

Among these 42 people:

How long have people been on Rasuvo when they have Weakness? *

What is the gender of people who have Weakness when taking Rasuvo? *

female: 88.1 %
male: 11.9 %

What is the age of people who have Weakness when taking Rasuvo? *

What are other drugs people take besides Rasuvo? *

Proair Hfa: 8 people, 19.05%
Lisinopril And Hydrochlorothiazide: 7 people, 16.67%
Advil: 7 people, 16.67%
Arnuity Ellipta: 7 people, 16.67%
Breo Ellipta: 7 people, 16.67%
Dulera: 7 people, 16.67%
Plaquenil: 7 people, 16.67%
Epipen: 7 people, 16.67%
Omeprazole: 7 people, 16.67%
Narcan: 7 people, 16.67%

What are other side effects people have besides Weakness? *

Nausea (feeling of having an urge to vomit): 15 people, 35.71%
Fatigue (feeling of tiredness): 14 people, 33.33%
Pain: 10 people, 23.81%
Headache (pain in head): 10 people, 23.81%
Pancreatitis Acute (sudden inflammation of pancreas): 7 people, 16.67%
Malaise (a feeling of general discomfort or uneasiness): 7 people, 16.67%
Sinusitis (inflammation of sinus): 7 people, 16.67%
Feeling Abnormal: 6 people, 14.29%
Nausea And Vomiting: 6 people, 14.29%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 6 people, 14.29%

What are the existing conditions these people have? *

Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 25 people, 59.52%
Immunodeficiency Common Variable: 7 people, 16.67%
Systemic Lupus Erythematosus (an autoimmune disease, which means the body's immune system mistakenly, attacks healthy tissue): 2 people, 4.76%
Ulcerative Colitis (inflammatory bowel disease (ibd). it causes swelling, ulcerations, and loss of function of the large intestine): 1 person, 2.38%
Soft Tissue Disorder (disease of soft tissue): 1 person, 2.38%
Polymyositis (inflammatory muscle disease that causes weakness of the skeletal muscles): 1 person, 2.38%
Polychondritis (progressive inflammation of cartilage and other connective tissue): 1 person, 2.38%
Osteoporosis (bones weak and more likely to break): 1 person, 2.38%
Osteoarthritis (a joint disease caused by cartilage loss in a joint): 1 person, 2.38%
Neuropathy Peripheral (surface nerve damage): 1 person, 2.38%

* Approximation only. Some reports may have incomplete information.

Do you take Rasuvo and have Weakness?

- Check whether Weakness is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Rasuvo:

Rasuvo (3,702 reports)

Weakness treatments and more:

Weakness (586,876 reports)

Browse all side effects of Rasuvo:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Weakness:

Weakness (3,642 drugs)

Browse all the conditions that are associated with Weakness:

Weakness (6,611 conditions)

Related publications that referenced our studies

Mathai, P. C., Andrade, N. N., Aggarwal, N., Nerurkar, S., & Kapoor, P. , "Low-dose methotrexate in rheumatoid arthritis: a potential risk factor for bisphosphonate-induced osteonecrosis of the jaw", Oral and maxillofacial surgery, 2018 Jan .
Mathai, P. C., Andrade, N. N., Aggarwal, N., Nerurkar, S., & Kapoor, P. , "Low-dose methotrexate in rheumatoid arthritis: a potential risk factor for bisphosphonate-induced osteonecrosis of the jaw", Oral and maxillofacial surgery, 2018 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on methotrexate (the active ingredients of Rasuvo) and Rasuvo (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.